Temasek launches up to US$25m selldown in Shanghai Pharma: IFR
[HONG KONG] Singapore state investor Temasek Holdings on Tuesday launched a selldown of up to US$25 million in Shanghai Pharmaceuticals, IFR reported, citing a term sheet of the transaction.
Temasek is offering 8 million shares of Shanghai Pharmaceuticals in an indicative range of HK$23.55 to HK$24.30 each, equivalent to a discount of up to 3 per cent to Tuesday's close, added IFR, a Thomson Reuters publication.
Goldman Sachs was hired as sole bookrunner of the selldown, the terms showed.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop
Cordlife customers push for legal action
Apparel company Express seeks quick bankruptcy sale